Complementary treatment of acute heart failure in patients with diabetes, chronic obstructive pulmonary disease or anemia;Tratamiento complementario de la insuficiencia cardíaca aguda en el paciente con diabetes, enfermedad pulmonar obstructiva crónica o anemia

Medicina Clinica

Volumn 142, Issue SUPPL. 1, 2014, Pages 59-65

  Carrasco Sánchez, Francisco Javier ^a   Iglesias, Jesús Recio ^b   Amorós, Jordi Grau ^c  

^a HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Hospital Municipal de Badalona   (Spain)

Author keywords

Acute heart failure; Anemia; COPD; Diabetes; Treatment

Indexed keywords

IRON; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; DIURETIC AGENT;

ACUTE HEART FAILURE; ALTERNATIVE MEDICINE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HYPERGLYCEMIA; IRON DEFICIENCY ANEMIA; IRON THERAPY; PROGNOSIS; STRESS; ACUTE DISEASE; ANEMIA, IRON-DEFICIENCY; BLOOD; CARDIO-RENAL SYNDROME; COMPLICATION; HEART FAILURE; NONINVASIVE VENTILATION; OXYGEN THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACUTE DISEASE; ANEMIA, IRON-DEFICIENCY; CARDIO-RENAL SYNDROME; CARDIOVASCULAR AGENTS; COMORBIDITY; DIABETES COMPLICATIONS; DIURETICS; HEART FAILURE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; IRON; NONINVASIVE VENTILATION; OXYGEN INHALATION THERAPY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84902955476     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(14)70085-5     Document Type: Article

References (79)

1. Van Melle JP, Bot M, De Jonge P, De Boer RA, Van Veldhuisen DJ, Whooley MA. Diabetes, glycemic cont rol, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33:2084-9.
2. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010;55:300-5.
3. Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Liem AH, Rutten GE, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154-62.
4. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee S G, and Investigators. Risk stratification for inhospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-80.
5. Andersson C, Weeke P, Pecini R, Kjaergaard J, Hassager C, Køber L, et al. Long-term impact of diabe tes in patients hospitalized with ischemic and non-ischemic heart failure. Scand Cardiovasc J. 2010;44:37-44.
6. Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;154:277 e1-8.
7. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Køber L, et al. Influence of diabet es and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771-7.
8. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, et al. Characteristics, outc omes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail. 2010;12:239-48.
9. Parissis JT, Rafouli-Stergiou P, Mebazaa A, Ikonomidis I, Bistola V, Nikolaou M, et al. Acute heart f ailure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol. 2012;157:108-13.
10. Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail. 2013;15: 194-202.
11. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of h yperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16-38.
12. Murad MH, Coburn JA, Coto-Yglesias F, Dzyubak S, Hazem A, Lane MA, et al. Glycemic control in non-cr itically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:49-58.
13. Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, et al. Association between elevated blo od glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol. 2013;61:820-9.
14. Dungan KM, Osei K, Nagaraja HN, Schuster DP, Binkley P. Relationship between glycemic control and re admission rates in patients hospitalized with congestive heart failure during implementation of hospital-wide initiatives. Endocr Pract. 2010;16:945-51.
15. Dungan KM, Binkley P, Nagaraja HN, Schuster D, Osei K. The effect of glycaemic control and glycaemic variability on mortality in patients hospitalized with congestive heart failure. Diabetes Metab Res Rev. 2011;27:85-93.
16. Dungan KM, Han W, Miele A, Zeidan T, Weiland K. Determinants of the accuracy of continuous glucose monitoring in non-critically ill patients with heart failure or severe hyperglycemia. J Diabetes Sci Technol. 2012;6:884-91.
17. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4:53-8.
18. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345-51.
19. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395-402.
20. Hernandez A V, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a metaanalysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115-28.
21. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773-8.
22. Giles TD, M iller AB, Elkayam U, Bhattacharya M, Pérez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14:445-52.
23. Khan MA, Dea ton C, Rutter MK, Neyses L, Mamas MA. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev. 2013;18:141-8.
24. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
25. White WB, Ca nnon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35.
26. Murcia AM, H ennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med. 2004;164:2273-9.
27. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377-85.
28. Masoudi FA, I nzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583-90.
29. Lind M, Olsso n M, Rosengren A, Svensson AM, Bounias I, Gudbjornsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012;55:2946-53.
30. Aguilar D, Bo zkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009;54:422-8.
31. American Diab etes A. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36 Suppl 1:S11-66.
32. Global Strate gy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. Global Iniciative for Chronic Obstructive Lung Disease (actualización 2013). Disponible en: wwwgoldcopdorg
33. Almagro P, Cab rera FJ, Díez J, Boixeda R, Alonso Ortiz MB, Murio C, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de Medicina Interna (ESMI) study. Chest. 2012;142:1126-33.
34. Cohn JN, Tognon i G; Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med. 2001;345:1667-75.
35. Mentz RJ, Fiuza t M, Wojdyla DM, Chiswell K, Gheorghiade M, Fonarow GC, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail. 2012;14:395-403.
36. Iversen KK, Kja ergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010;12:685-91.
37. Maisel AS, McCo rd J, Nowak RM, Hollander JE, Wu AH, Duc P, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003;41:2010-7.
38. Karnani NG, Rei sfield GM, Wilson GR. Evaluation of chronic dyspnea. Am Fam Physician. 2005;71:1529-37.
39. Holleman DR Jr, Simel DL, Goldberg JS. Diagnosis of obstructive airways disease from the clinical examination. J Gen Intern Med. 1993;8:63-8.
40. Badgett RG, Tan aka DJ, Hunt DK, Jelley MJ, Feinberg LE, Steiner JF, et al. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med. 1993;94:188-96.
41. Singer AJ, Emer man C, Char DM, Heywood JT, Kirk JD, Hollander JE, et al. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. Ann Emerg Med. 2008;51:25-34.
42. Egred M, Shaw S , Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005;98:493-7.
43. Salpeter SR, Or miston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective betablockers for chronic obstructive pulmonary disease: a meta-analysis. Resp Med. 2003;97:1094-101.
44. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63:301-5.
45. Bermingham M, O Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, et al. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail. 2011;13:885-91.
46. Salpenter RS. D o inhaled anticholinergics increase or decrease the risk of major cardiovascular events? A synthesis of the available evidence. Drugs. 2009;69:2025-33.
47. Celli B, Decram er M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20-30.
48. Calverley PM, A nderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65:719-25.
49. Rusinaru D, Saa idi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol. 2008;101:353-8.
50. Guía de práctic a clínica de la Sociedad Europea de Cardiología (ESC). para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2012) Rev Esp Cardiol. 2012. 65 938.e1-59
51. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-7.
52. Dahl R, Chung KF, Buh l R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-9.
53. Wise RA, Anzueto A, C otton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat inhaler and the risk of death in COPD. New Engl J Med. 2013;369:1491-501.
54. DUrzo A, Kerwin E, R ennard S, He T, Gil EG, Caracta C. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD. 2013;10:500-10.
55. Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis. 2012;7:673-8.
56. Pinsky MR. Cardiovasc ular issues in respiratory care. Chest. 2005;128:592S-7S.
57. Llorens P, Martín-Sánchez FJ, González- Armengol JJ, Herrero P, Jacob J, lvarez AB, et al. Perfil clínico del paciente con insuficiencia cardiaca aguda atendido en los servicios de urgencias: Datos preliminares del Estudio EAHFE (Epidemiology Acute Heart Failure Emergency). Emergencias. 2008;20:154-63.
58. Grigorian-Shamagian L, V arela-Román A, Mazón-Ramos P, Pedreira-Pérez M, Rigueiro-Veloso P, González-Juanatey J. Anemia as a new predictor of mortality in patients hospitalized with congestive heart failure. Med Clin (Barc). 2005;125: 647-53.
59. García de Casasola G, Carden as Franco C, Vegas Serrano A, Hornero Izquierdo MA, Guijarro Herraiz C, Zapatero Gaviria A. Anaemia predicts mortality in heart failure. Anales de Medicina Interna. 2005;22:271-4.
60. Formiga F, Chivite D, Castane r O, Manito N, Ramon JM, Pujol R. Anemia in newonset congestive heart failure inpatients admitted for acute decompensation. Eur J Int Med. 2006;17:179-84.
61. Domínguez Franco A, Pena Hern ández J, Pérez Caravante M, Mun∼oz García A, Jiménez Navarro M, De Teresa Galván E. Long-term prognosis value of anemia in a non-selected population with heart failure. Med Clin (Barc). 2007;128:370-1.
62. Grau-Amorós J, Formiga F, Jordana-Co majuncosa R, Urrutia A, Aramburu Bodas O, Ceresuela LM; GESAIC Study. Anemia prevalence in heart failure. GESAIC study results. Rev Clin Esp. 2008;208:211-5.
63. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107:226-9.
64. Grau Amorós J, Formiga F, Jordana Com ajuncosa R, Urrutia A, Arias Jiménez JL, Salvador Mínguez JP; Investigadores del Estudio GESAIC. Etiology and clinical management of anemia in heart failure. GESAIC Study. Med Clin (Barc). 2009;132:447-53.
65. Van der Meer P, Postmus D, Ponikowski P, Cleland JG, OConnor CM, Cotter G, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol. 2013;61:1973-81.
66. Mentz RJ, Felker GM. Noncardiac comorbid ities and acute heart failure patients. Heart Fail Clin. 2013;9:359-67, vii.
67. Rovellini A, Graziadei G, Folli C, Bramb illa AM, Cosentini R, Canetta C, et al. Causes and correlates of anemia in 200 patients with acute cardiogenic pulmonary edema. Eur J Intern Med. 2012;23:733-7.
68. Pisaniello AD, Wong DT, Kajani I, Robins on K, Shakib S. Anaemia in chronic heart failure: more awareness is required. Intern Med J. 2013;43:999-1004.
69. Domínguez JP, Harriague CM, García-Rojas I, González G, Aparicio T, González- Reyes A. Acute heart failure in patients over 70 years of age: Precipitating factors of decompensation. Rev Clin Esp. 2010;210:497-504.
70. Groenveld HF, Januzzi JL, Damman K, Van Wijn gaarden J, Hillege HL, Van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-27.
71. Zairis MN, Patsourakos NG, Georgilas AT, Mel idonis A, Argyrakis KS, Prekates AA, et al. Anemia and early mortality in patients with decompensation of chronic heart failure. Cardiology. 2011;119:125-30.
72. Grau-Amorós J, Formiga F, Aramburu O, Recio- Iglesias J, Trullas JC, Urrutia A. Anemia in heart failure: its usefulness as prognosis or comorbidity marker: GESAIC-2 study. Med Clin (Barc). 2012;138:656-9.
73. Garty M, Cohen E, Zuchenko A, Behar S, Boyko V, Iakobishvili Z, et al; Heart Failure Survey in ISrael (HFSIS) Investigators. Blood transfusion for acute decompensated heart failure-friend or foe? Am Heart J. 2009;158:653-8.
74. Kao DP, Kreso E, Fonarow GC, Krantz MJ. Chara cteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006). Am J Cardiol. 2011;107:69-73.
75. Llorens P, Martín Sánchez FJ, Herrero Puente P, Jacob Rodríguez J, Gil V. Manejo de la insuficiencia cardiaca aguda en los servicios de urgencias, emergencias y unidades adscritas. Documento de consenso del Grupo de Insuficiencia Cardiaca Aguda de la Sociedad Espan∼ola de Medicina de Urgencias y Emergencias (ICASEMES). Emergencias. 2011;23:119-39.
76. Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuo li A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011;161:822-31 e2.
77. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS , Díaz R, et al; RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. New Engl J Med. 2013;368:1210-9.
78. Maurer MS, Teruya S, Chakraborty B, Helmke S, Manc ini D. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy. Circ Heart Fail. 2013;6:254-63.
79. Anker SD, Comin Colet J, Filippatos G, Willenheime r R, Dickstein K, Drexler H, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. New Eng J Med. 2009;361:2436-48.